

The International Lung GVHD Consensus Conference 2026

23-25 SEPTEMBER 2026

CAMPUS BIOTECH, GENEVA, SWITZERLAND

Hôpitaux Universitaires Genève

UNIVERSITÉ DE GENÈVE

FACULTÉ DE MÉDECINE

DAY 1: PATHOGENESIS OF LUNG GVHD

Wednesday 23 September 2026

GOAL: Synthesize preclinical understanding of the pathogenesis of BOS that occurs in the context of allogeneic hematopoietic cell transplant, identify translatable targets and key priorities for preclinical investigation

Co-Chairs: Joe Hsu and Sophie Paczesny

08:15 Welcome participants

08:30 Opening Remarks *Prof Antoine Geissbuhler, Dean of the University of Geneva*

08:35 Building on the ATS research statement and our understanding of the natural history of BOS *Guang-Shing Cheng, Fred Hutchinson Cancer Center*

08:50 Session 1: Knowledge Review

08:50 Beyond the small airways: Mapping allo-immune and transplant-related lung injury after HCT *Anne Bergeron, University of Geneva*
09:05 Heterogeneity of airway pathology in clinical BOS: insights from microCT investigations in HCT, LT, and PIBO *Stijn Verleden, University of Antwerp*
09:25 Airway epithelium as disease nexus in alloimmune lung injury *Jamie Todd, Duke University*
09:45 Peripheral helper T cells, B cells, and tertiary lymphoid structures in CLAD: do these pathways translate to lung GVHD? *Stephen Juvet, University of Toronto*
10:05 The role of macrophages, cellular immunity, and alloimmune pathways in chronic GVHD *Julie Boiko, Fred Hutchinson Cancer Center*
10:25 Discussion

10:35 ***Break***

10:45 Session 2: Knowledge Review

10:45 Role of infection and microbiome in post-HCT lung injury *Matthew Zinter, University of California San Francisco*
11:05 Dysbiosis and metabolomics in lung GVHD *David Michonneau, University Paris Cité*
11:25 Respiratory virus as a trigger for HCT-BOS *Louise Bondeelle, University of Geneva*
11:45 Lessons from bronchiectasis: phenotypes, endotypes, and treatable traits *Alan Barker, Oregon Health and Science University*
12:05 Discussion

12:15 ***Lunch***

13:15 The Patient Perspective *Andreas Mall, Germany*

13:20 Session 3: Pro/Con Debate: Are early pulmonary inflammation and endothelial injury risk factors for LONIPC or BOS *Kenneth Cooke, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Ajay Sheshadri, MD Anderson Cancer Center*
13:50 Discussion

14:00 Session 4: Pathways of Fibrosis Across Medical Contexts

14:00 Multiple pathways towards fibrogenesis in idiopathic pulmonary fibrosis *Bruno Crestani, Université Paris Cité*
14:20 Risk and mechanisms of CLAD *John Belperio, David Geffen School of Medicine, University of California Los Angeles*
14:40 Targeting pulmonary fibrosis in chronic GVHD mice with lung dysfunction *Bruce Blazar, University of Minnesota*
15:00 Discussion

15:10 ***Break***

15:20 Session 5: Translational approaches to studying lung GVHD

15:20 Cell-free DNA: sensitive predictive biomarker for pulmonary GVHD / CLAD risk *Sean Agbor-Enoh, NIH/NHLBI*
15:40 Murine models of bronchiolitis obliterans and transplant pulmonary fibrosis *Joe Hsu, Stanford University*
16:00 Modeling HCT-BOS with patient bronchoalveolar lavage fluid-derived organoids *Carla Kim, Boston Children's Hospital and Harvard Medical School*
16:20 Multi-omic analyses of human lung explants in HCT-BOS and CLAD *Patrick Mellors, Dartmouth University*
16:40 Discussion

16:50 Session 6: Plenary Discussion

17:20 ADJOURN Day 1

18:30 Networking Reception

DAY 2: UPDATING THE NIH DEFINITION OF BOS

Thursday 24 September 2026

GOAL: To derive a consensus revision of the HCT-BOS diagnostic criteria and conceptual framework for defining lung chronic GVHD.

Co-Chairs: Guang-Shing Cheng and Anne Bergeron

08:20 Session 1: Introduction of the Lung cGVHD Framework

Rationale for a revision of the 2014 NIH Definition of BOS: Why do we need this now? *Anne Bergeron, University of Geneva and Daniel Wolff, University Hospital Regensburg*

The historical context of the NIH cGVHD Consensus Project *Steven Pavletic, NIH*

The diagnostic framework and introduction of the working proposal *Guang-Shing Cheng, Fred Hutch Cancer Center*

08:50 Session 2: Diagnostic Elements of BOS: Lung Physiology and Chest Imaging

08:50 *Lung Physiology* Guang-Shing Cheng (Lead)

The natural history of BOS *Guang-Shing Cheng, Fred Hutch Cancer Center*

Current interpretative strategies and PFT change metrics across the lifespan *Hemang Yadav, Mayo Clinic*

Pathologic correlations with lung physiology and defining pulmonary impairment *Gerald Weinhouse, Dana Farber Cancer Institute/Harvard University*

Patterns of airflow obstruction, small airways disease, and 'reversibility' in BOS *Jane Turner, McMaster University*

Current and future alternatives to conventional PFTs: MBW, oscillometry and home spirometry *Paul Robinson, University of Melbourne*

09:30 *Discussion* *Nicola Adderley, Paul Robinson, Matthew Rutter, Hélène Salvator, Jane Turner, Gerald Weinhouse, Hemang Yadav, Guang-Shing Cheng*

09:50 *Chest Imaging* Husham Sharifi (Lead)

Chest imaging correlates of airflow obstruction *Okka W. Hamer, University of Regensburg*

The future: Quantitative CT, MRI, and novel approaches to imaging for lung GVHD *Gregory Yanik, University of Michigan*

10:10 *Discussion* Edward Castillo, Julien Cohen, Craig Galban, Jörg Halter, Okka W. Hamer, Jonathan H. Rayment, Gregory Yanik, Husham Sharifi

10:30 ***Break***

10:45 Session 3: Diagnostic Elements of BOS: Necessary Conditions, Exclusions, and Considerations for Special Populations

10:45 *Conditions* Ajay Sheshadri (Lead)

Requirements for the presence of extrapulmonary cGVHD to diagnose BOS *Catherine Lee, Fred Hutchinson Cancer Center*

Should absence of infection be a necessary requirement? *David Epstein, Stanford University*

The need for lung biopsy to diagnose lung cGVHD *Clare Sander, Cambridge University Hospital and Alicja Sadowska-Klasa, Medical University of Gdansk*

11:05 *Discussion* Louise Bondeelle, David Epstein, Samuel Goldfarb, Matthew Hensley, Catherine Lee, Alicja Sadowska-Klasa, Clare Sander, Ajay Sheshadri

11:25 *Pediatrics and Special Populations* Kirsten Williams (Lead)

The impact of growth on lung function and diagnostic considerations in children after HCT *Shiv Shanthikumar, University of Melbourne*

The minimum diagnostic criteria if no diagnostic testing can be obtained *Kirsten Williams, Emory University*

11:40 *Discussion* Shiv Shanthikumar, Stella Davies, Véronique Houdouin, Anita Lawitschka, Kirk Schultz, Hemang Yadav, Kirsten Williams

12:00 ***LUNCH***

13:00 Session 4: Non-BOS Lung cGVHD

Jeff Sturek and Anne Bergeron (co-Leads)

13:00 Restrictive physiology, extrapulmonary cGVHD, and mixed phenotypes *Jeff Sturek, University of Virginia*

Interstitial lung disease including organizing pneumonia, NSIP *Yu-Kuang Lai, Stanford University*

13:30 *Discussion*

Non-BOS Lung Disease Group: Mark Barash, Saskia Bos, Geoff Cuvelier, Katrin Hostettler, Joe Hsu, Yu-Kuang Lai, Steven Pavletic, Jeffrey Sturek and Anne Bergeron

14:00 Session 5: Screening and Implementation Recommendations Panel Discussion *Daniel Wolff and Group Panelists with an introduction by Guy Livneh, Palo Alto, CA*

Implementation Group: Paul Carpenter, Yves Chalandon, Anna DeSalvo, Najla El Jurdi, Samuel Goldfarb, John Murray, Danielle Stahlbaum, Daniel Wolff

15:00 ***Break***

15:15 Session 6: Plenary Discussion: Addressing Areas of Uncertainty and Future Directions

16:45 ADJOURN Day 2

DAY 3: CLINICAL TRIALS FOR LUNG GVHD — Friday 25 September 2026

GOAL: Establish an ideal clinical trial design and identify clinical trial readiness gaps for Lung GVHD after HCT

Co-Chairs: Anne Bergeron and Guang-Shing Cheng

08:00 **Introduction: Why we need lung chronic GVHD-specific clinical trials** *Corey Cutler, Dana Farber Cancer Institute/Harvard University*

08:10 **Session 1: Current Therapeutic Landscape for HCT-BOS**
08:10 Guidelines versus the reality *Hélène Schoemans, University Hospitals of Leuven*
08:25 Regulatory-approved cGVHD medications: a pulmonologist's perspective *Anne Bergeron, University of Geneva*
08:40 Antifibrotics and the pulmonary drug pipeline *Katrin Hostettler, University of Basel*
08:55 Alternative therapies and cGVHD drug pipeline *Daniel Wolff, University of Regensburg*
09:10 Discussion

09:25 ***Break***

09:30 **Session 2: Clinical Trial Design Elements**
09:30 Current NIH response criteria, endpoints and limitations *Guang-Shing Cheng, Fred Hutchinson Cancer Center*
09:45 When it's OK to be out of line – modeling continuous data as a non-linear function *Ted Gooley, Fred Hutchinson Cancer Center*
10:00 How to Improve the Level of Evidence of Single-Arm Phase 2 Trials. *Sylvie Chevret, University Paris Cité/Hôpital St. Louis*
10:15 Biomarkers for Lung GVHD: how do we get there, and how do we test? *Sophie Paczesny, Medical College of South Carolina*
10:30 Innovative trial designs in interstitial lung diseases: adaptive, umbrella, basket *Toby Maher, University of Southern California*
10:45 Discussion

11:00 **Insights from the Facebook BOS group:** What patients are willing to do to participate in a clinical trial. *Guy Livneh, Palo Alto, California*

11:15 ***BREAK/LUNCH***

11:45 **Session 3: Clinical Trial Partnerships Panel Discussion**
Co-Chairs: Daniel Wolff and Steven Pavletic
Panelists: Val Bhatt (Incyte), Dawn Reichenbach (Sanofi), Jason Chien (JWC Global Consulting LLC), Gino Cortopassi (Buto Corp.), Madhuri Vusirikala (Therakos), Guy Livneh (Patient Advocate)

12:55 ***Break***

13:00 **Session 4: Clinical Trial Design Brainstorming Session**
13:00 Small group breakouts: 1) Overall Trial Design, 2) Trial Inclusion and Endpoints, 3) Agents to Test, 4) Correlative Studies, 5) Recruitment and Retention
Leads: Greg Yanik and Jamie Todd (1), Najla El Jurdi and Guang-Shing Cheng (2), Catherine Lee and Bruno Crestani (3), Sean Agbor-Enoh and José A. Pérez-Simón (4), Hélène Schoemans and Danielle Stahlbaum (5)
13:45 Group reports and discussion

14:30 **Session 5: Plenary Discussion: White Board Proposal for the Ideal Clinical Trial**

15:30 **SUMMARY and ADJOURN Day 3 and Conference**

The International Lung GVHD Consensus Conference 2026

Biographies

Name *Leadership Role in Conference*	**Bio**
Nicola Adderley, MD	**University of Calgary, Canada**. Dr. Adderley is an Affiliate Investigator at the FHCC and Clinical Lecturer at the Cumming School of Medicine, University of Calgary. She completed a year of clinical research training at the FHCC, focusing on the pathogenesis and natural history of bronchiolitis obliterans syndrome (BOS), as well as restrictive ventilatory impairment after stem cell transplant (HCT). Her clinical and research interests include pulmonary complications after HCT and drug-induced pneumonitis in the context of cancer therapy.
Sean Agbor-Enoh, MD, PhD *Breakout Lead*	**NIH/NHLBI, USA**. Dr. Agbor-Enoh is a Senior Investigator and Chief of the Laboratory of Applied Precision Omics at the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, and a Professor of Medicine at Johns Hopkins University. His research interests focus on transplant rejection and precision genomics. His work has pioneered the use of cell-free DNA for early detection of transplant rejection and the translation cell-free DNA into routine clinical practice as an alternative of biopsy. On going work tests the use of cell-free DNA to risk stratify patients for chronic lung allograft dysfunction (CLAD), HCT complications and other conditions.
Mark Barash, DO	**Medical College of Wisconsin, USA**. Dr. Barash is an assistant professor in the division of Pulmonary, Critical Care and Sleep Medicine. His interests focus on the diagnosis and management of patients with interstitial lung diseases and pulmonary complications of hematopoietic stem cell transplant.
Alan Barker, MD	**Oregon Health & Science University, USA**. Dr. Barker is a Professor of Medicine in the Division of Pulmonary, Allergy and Critical Care Medicine at Oregon Health & Science University (OHSU) and serves as Medical Director of the Pulmonary Function Laboratory. His clinical interests include COPD, bronchiectasis, lymphangioleiomyomatosis (LAM), and alpha-1 antitrypsin deficiency. His research focuses on bronchiectasis and other chronic lung diseases, including clinical trials and translational studies aimed at improving diagnosis and treatment outcome.
John Belperio, MD	**David Geffen School of Medicine, University of California Los Angeles, USA**. Dr. Belperio is a Professor of Medicine and Interim Chief of the Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology and Allergy at the David Geffen School of Medicine at UCLA. His clinical interests include lung transplantation, interstitial lung disease, pulmonary fibrosis, sarcoidosis, and critical care medicine. His research focuses on the immunologic and molecular mechanisms of lung allograft dysfunction and chronic rejection, as well as the pathogenesis of pulmonary fibrosis and other chronic lung diseases.

Name *Leadership Role in Conference*	**Bio**
Anne Bergeron, MD, PhD *Scientific Steering Committee Chair/Task Force Lead*	**University of Geneva, Switzerland**. Dr. Bergeron is the Head of the Division of Pulmonology at the Geneva University Hospitals (HUG) and Professor of Medicine at the University of Geneva (UNIGE). A pulmonologist with extensive expertise in onco-hematology–related lung disease, she specializes in the infectious and non-infectious pulmonary complications of hematopoietic stem cell transplantation. Her research program is focused on bronchiolitis obliterans, interstitial lung diseases, and the interaction between respiratory viruses and the airway epithelium in transplant recipients. She is widely regarded as a leading authority in transplant-related pulmonary complications and respiratory medicine.
Elodie Blanchard MD	**Bordeaux University Hospital, France**. Dr. Blanchard is a pulmonologist at Bordeaux University Hospital, France, where she specializes in respiratory infections, lung transplantation, and rare pulmonary diseases. She serves as Coordinator of the adult rare lung disease competency center (OrphaLung). Dr. Blanchard's research focuses on lung transplantation, chronic lung allograft dysfunction, interstitial and fibrotic lung diseases, bronchial remodeling, and advanced imaging approaches for pulmonary disease assessment. Her work integrates clinical and translational research aimed at improving the diagnosis, monitoring, and management of patients with rare and advanced respiratory disorders. *Acknowledgement: Thank you, Dr. Blanchard, for your contribution as an external reviewer.*
Bruce Blazar, MD	**University of Minnesota, USA**. Dr. Blazar is Regents Professor of Pediatrics in the Division of Blood and Marrow Transplant & Cellular Therapy at the University of Minnesota. His clinical and translational work focuses on hematopoietic cell transplantation, graft-versus-host disease (GVHD), cellular therapies, and immune regulation. His research has been instrumental in developing novel strategies to prevent and treat GVHD, improve post-transplant immune recovery, and advance regulatory T-cell and other immune-based therapies for transplant recipients.
Michael Boeckh, MD, PhD *Special Advisor*	**Fred Hutchinson Cancer Center, USA**. Dr. Boeckh is a professor at the University of Washington School of Medicine, Division of Allergy and Infectious Diseases and a professor at Fred Hutchinson in the Clinical Research Division. He is the program head of the Infectious Disease Sciences Program in the Vaccine and Infectious Disease Division. Dr. Boeckh is an expert in infections that affect people whose immune systems have been weakened by illness, chemotherapy or blood stem cell transplantation. His research focuses on herpes viruses, respiratory viruses and the genetic factors that make some individuals more susceptible to these infections.

Name *Leadership Role in Conference*	**Bio**
Julie Boiko, MD, PhD	**Fred Hutch Cancer Center, USA**. Dr. Boiko is a physician-scientist with a clinical and scientific focus on chronic graft-versus-host disease (cGVHD). Her research combines immunology and computational genomics to investigate the mechanisms of cGVHD, with a particular emphasis on myeloid cells, fibrosis, and improving long-term outcomes for transplant recipients. Clinically, she attends in the Seattle Children's Hospital Pediatric Blood and Marrow Transplant Program and the Fred Hutch adult Long-Term Follow-Up Program.
Louise Bondeelle MD, PhD	**University of Geneva, Switzerland**. Dr. Bondeelle is a pulmonologist and physician-scientist at the University of Geneva in the Department of Microbiology and Molecular Medicine. She divides her time between clinical care, primarily of allogeneic HCT recipients, in Anne Bergeron's Pulmonology service and research in Caroline Tapparel's laboratory. Their collaborative project investigates epithelial responses to viral exposure using ex vivo human epithelial cells from HCT recipients, aiming to better understand mechanisms of lung injury after HCT.
Saskia Bos MD, PhD	**University Hospitals Leuven, Belgium**. Dr. Bos is a transplant pulmonologist in the Leuven Lung Transplant Program and assistant professor at the Department of Chrometa at KU Leuven. She has a specific interest in chronic lung allograft dysfunction, pulmonary graft-versus-host disease after haematopoietic stem cell transplantation and infectious diseases in solid organ transplants.
Paul Carpenter, MBBS	**Fred Hutchinson Cancer Center, USA**. Dr. Carpenter is a professor at the University of Washington School of Medicine, Department of Pediatrics and a professor at FHCC in the Clinical Research Division. He is the Clinical Director of Long-Term Follow-Up at FHCC. He is also an attending physician at Seattle Children's Hospital. A major focus of Dr. Carpenter's research is developing better treatments for short- and long-term graft-versus-host disease (GVHD). He co-chairs the Committee on Practice Guidelines for the American Society for Transplantation and Cellular Therapy, helping develop clinical practice guidelines for hematopoietic stem cell transplantation that reflect the latest scientific evidence.
Edward Castillo, PhD	**University of Texas at Austin, USA**. Dr. Castillo is an associate professor in the Department of Biomedical Engineering at UT Austin and an adjunct associate professor of computational and applied mathematics (CAAM) at Rice University. His research program is focused on the theoretical development, implementation and clinical application of numerical methods for medical image analysis. In collaboration with medical physicists, he has pioneered computational methods for inferring patient-specific functional tissue properties from dynamic medical imaging.

Name *Leadership Role in Conference*	**Bio**
Yves Chalandon, MD	**University of Geneva, Switzerland**. Dr. Chalandon is a renowned hematologist and Professor of Medicine at the University of Geneva (UNIGE) , Switzerland. He serves as the Head of the Hematology Division at the Geneva University Hospitals (HUG), where he leads a specialized research group focused on advancing new leukemia treatments, preventing graft-versus-host disease (GVHD), and exploring stem cell gene therapy. He is the president of the Swiss Society of Hematology. He is widely regarded as a leading authority in allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia.
Guang-Shing Cheng, MD *Scientific Steering Committee Chair/Task Force Lead* *Breakout Lead*	**Fred Hutchinson Cancer Center, USA**. Dr. Cheng is a professor of Pulmonary, Critical Care and Sleep Medicine at the University of Washington School of Medicine, Division of Pulmonology and a professor at FHCC in the Clinical Research Division. She is the medical director of the Pulmonary Outpatient Consult Service. Dr. Cheng's research is dedicated to improving outcomes for patients who develop lung complications following blood stem cell transplantation. Her primary area of interest is bronchiolitis obliterans syndrome (BOS).
Sylvie Chevret, MD, PhD	**University of Paris, France**. Dr. Chevret is a Professor of Biostatistics at Université Paris Cité and leads the Biostatistics and Clinical Epidemiology team at Institut de Recherche Saint-Louis in Paris. Her work focuses on clinical trial methodology, Bayesian statistics, causal inference, and clinical epidemiology. She collaborates extensively in hematology and hematopoietic cell transplantation research, developing innovative statistical approaches to improve therapeutic evaluation and patient outcomes.
Jason Chien, MD, MS	**JWC Global Consulting, LLC, Seattle, USA.** Dr. Chien is an Infectious Disease, Pulmonary and Critical Care physician by training and was formerly on faculty at the University of Washington and Fred Hutchinson Cancer Center where he led an NIH funded translational lab that made seminal scientific observations in BOS, contributing significantly to the field of lung GVHD. Since leaving academia, he has advanced multiple novel therapeutics in the pharmaceutical industry spanning indications in fibrosis, airways diseases, infectious diseases and autoimmune diseases.
Julien Cohen, MD, PhD	**University of Geneva, Switzerland**. Dr. Cohen is a radiologist specializing in thoracic and oncological imaging. He serves as attending physician in charge of the Oncological and Thoracic Radiology Unit at Geneva University Hospitals (HUG). His main research areas focus on the imaging of lung adenocarcinomas, including work cited in the international recommendations of the Fleischner Society, the imaging of diffuse interstitial lung diseases (ILD), thoracic applications of photon counter CT (PCCT), and artificial intelligence applied to thoracic imaging.

Name *Leadership Role in Conference*	**Bio**
Kenneth Cooke, MD	**Johns Hopkins University, USA**. Dr. Cooke is the Herman and Walter Samuelson Professor of Oncology and Pediatrics and Director of the Pediatric Blood and Marrow Transplantation Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. His clinical and research interests focus on allogeneic hematopoietic cell transplantation, graft-versus-host disease (GVHD), and noninfectious pulmonary complications following transplantation. He is a member of the American Society for Clinical Investigation, and his translational research examines the immunologic and inflammatory mechanisms underlying GVHD and lung injury, with the goal of developing novel strategies to prevent and treat transplant-related complications. *Acknowledgement: Thank you, Dr. Cooke, for your contribution as an external reviewer.*
Bruno Crestani, MD, PhD *Breakout Lead*	**Université Paris Cité, France**. Dr. Crestani is a Professor of Pulmonology and the Head of the Department of Pneumology at Bichat-Claude Bernard Hospital in Paris, France. He also serves as Coordinator of the adult Reference Center for Rare Lung Diseases and is a Research Director at Inserm and Université Paris Cité, where his work focuses on the pathophysiology of inflammatory and fibrotic lung diseases. He leads research programs focused on inflammatory and fibrotic lung disorders and has made major contributions to clinical research, guideline development, and patient care in respiratory medicine.
Corey Cutler, MD, MPH *Scientific Steering Committee*	**Dana-Farber Cancer Institute/Harvard University, USA**. Dr. Cutler is a Professor of Medicine at Harvard Medical School and a senior physician in the Hematologic Malignancies and Stem Cell Transplantation programs at Dana-Farber Cancer Institute. He serves as Physician Director of the Adult Stem Cell Transplantation Program. Dr. Cutler's research focuses on allogeneic hematopoietic stem cell transplantation, graft-versus-host disease, transplant survivorship, and clinical outcomes in patients with hematologic malignancies.
Geoff Cuvelier, MD, FRCPC	**Alberta Children's Hospital, Canada**. Dr. Cuvelier is a pediatric transplant physician and Clinical Professor at the Alberta Children's Hospital and University of Calgary in Calgary. He is the Section Head of Pediatric Oncology and Stem Cell Transplantation at the Alberta Children's Hospital. His research interests include chronic GVHD in children, leading studies into clinical validation of the NIH criteria for pediatric chronic GVHD diagnosis, biomarkers of chronic GVHD, and the NIH consensus project into atypical chronic GVHD.

Name *Leadership Role in Conference*	**Bio**
Stella Davies MBBS, PhD	**Cincinnati Children's Hospital, USA**. Dr. Davies is a professor in the Department of Pediatrics at the University of Cincinnati, Director of the Division of Bone Marrow Transplantation and Immune Deficiency, and Institute Co-Executive Director of the Cancer and Blood Diseases Institute in Cincinnati. She is also president-elect of the American Society of Transplantation and Cellular Therapy. She specializes in bone marrow transplantation with a focus on finding out what causes complications after bone marrow transplantation to determine better ways to fix these complications.
Zachariah DeFilipp, MD	**Mass General Brigham/Harvard, USA**. Dr. DeFilipp is Associate Professor of Medicine at Harvard Medical School, Director of the Bone Marrow Transplant Program at the Mass General Brigham Cancer Institute. His research focuses on improving outcomes after allogeneic hematopoietic cell transplantation, with particular emphasis on the prevention and treatment of acute and chronic graft-versus-host disease (GVHD), transplant-related complications, survivorship, and clinical trials evaluating novel therapeutic approaches for patients undergoing stem cell transplantation.
Anna DeSalvo, MS, CGC	**National Marrow Donor Program, USA**. Anna DeSalvo is a board certified and licensed genetic counselor and Senior Manager of Implementation Science at Center for International Blood and Marrow Transplant Research (CIBMTR) NMDP. She helps translate research findings into meaningful programs and standardized practice in order to provide the best care and outcomes for patients.
Najla El Jurdi, MD *Breakout Lead*	**NIH/NCI, USA**. Dr. El Jurdi is an associate research physician in the Immune Deficiency Cellular Therapy Program. As a hematopoietic cell transplantation and cellular therapy physician, she focuses on clinical and translational investigations to better understand, prevent, and treat Graft-versus-Host Disease (GVHD), with a particular emphasis on chronic GVHD. She works to leverage the expertise of the NIH GVHD multidisciplinary team and intramural program to bring forth novel clinical trials and therapeutic approaches for GVHD.
David Epstein, MD	**Stanford University, USA**. Dr. Epstein is a Clinical Assistant Professor of Medicine in Infectious Diseases at Stanford. His clinical and research interests focus on infectious and pulmonary complications arising from bone marrow transplantation (BMT), chimeric antigen receptor T-cell (CAR-T) therapy, and other cancer treatments. His current research investigates bronchiectasis and nontuberculous mycobacterial (NTM) infections as complications associated with lung graft-versus-host disease (GVHD) and CAR-T therapy.

Name *Leadership Role in Conference*	**Bio**
Craig Galban, PhD	**University of Michigan, USA**. Dr. Galban is a Professor of Radiology at the University of Michigan School of Medicine and has affiliated appointments in the Departments of Computational Medicine and Bioinformatics and Biomedical Engineering. His research is focused on the development and analysis of surrogate imaging markers for phenotyping pulmonary diseases.
Samuel Goldfarb, MD	**University of Minnesota, USA**. Dr. Goldfarb is Professor and Division Director of the Division of Pediatric Pulmonary & Sleep Medicine, Director of the Pediatric Cystic Fibrosis Program, and Co-Director of the University of Minnesota Cystic Fibrosis Center. His clinical and research interests include cystic fibrosis, pulmonary disease following hematopoietic cell transplantation (HCT), interstitial lung disease, and early and late pulmonary complications of cancer therapy. His research has a particular focus on the early detection, longitudinal assessment, and outcomes of pulmonary complications following HCT, including bronchiolitis obliterans syndrome and other forms of chronic lung disease. He is also actively involved in research on novel approaches to assessing lung function in children with pulmonary disease, including those unable to perform conventional pulmonary function testing.
Ted Gooley, PhD	**Fred Hutchinson Cancer Center, USA**. Ted Gooley is a Professor in the Clinical Research Division and Public Health Sciences Division at Fred Hutch Cancer Center and Director of Clinical Biostatistics. His expertise centers on the design, analysis, and interpretation of clinical trials and observational studies, particularly in hematopoietic cell transplantation and cellular therapy. His research focuses on biostatistical methods, transplant outcomes research, and the application of quantitative approaches to improve clinical investigation in cancer and transplantation.
Jörg Halter, MD	**University Hospital Basel, Switzerland**. Dr. Halter is Chief Physician of the Hematology clinic at University Hospital Basel and is Head of the Stem Cell Transplantation Treatment Center. His clinical practice focuses on adult hematopoietic stem cell transplantation and the comprehensive management of complex hematologic malignancies. His research interests center on optimizing long-term post-transplant outcomes, with a particular emphasis on the pathophysiology, prevention, and therapeutic management of chronic Graft-versus-Host Disease (cGvHD), as well as the assessment of cardiovascular risks and metabolic complications in transplant survivors.

Name *Leadership Role in Conference*	**Bio**
Okka W. Hamer, MD	**University of Regensburg, Germany**. Dr. Hamer is a highly specialized radiologist at the University Hospital Regensburg, leads the Cardiopulmonary Imaging section, and serves as the Chief of Radiology at Donaustauf Hospital. Her focus includes advanced CT and MRI imaging techniques for complex heart and lung diseases, specifically investigating thoracic malignancies, interstitial lung diseases, and pulmonary hypertension. Her clinical research aims to optimize non-invasive diagnostic precision, bridging high-resolution radiological imaging with improved patient outcomes in cardiopulmonary medicine.
Matthew Hensley, MD	**University of Pittsburgh Medical Center, USA**. Dr. Hensley is Assistant Professor of Medicine in Pulmonary, Allergy, Critical Care, and Sleep Medicine at University of Pittsburgh. His research interests are broadly focused on trying to understand the mechanisms of pulmonary complications post-HCT through microbial sequencing techniques and host response phenotyping. He has additional interest in outcomes of CAR-T and immunotherapy-related critical illness and interest in both acute and late complications of HCT including infectious and non-infectious complications such as pulmonary graft-versus-host disease.
Katrin Hostettler, MD, PhD	**University of Basel, Switzerland**. Dr. Hostettler is a Professor of Pulmonary Medicine and Interim Chief of the Division of Pulmonology at the University Hospital Basel. Her clinical practice centers on interstitial lung diseases, with a particular focus on idiopathic pulmonary fibrosis, sarcoidosis and chronic Graft-versus-Host Disease (cGvHD). Her basic research is focused on pulmonary stem cell biology using primary human cell models.
Véronique Houdouin, MD, PhD	**Robert-Debré University Hospital, France**. Dr. Houdouin is Head of the Pediatric Pulmonology, Allergology, and Cystic Fibrosis Department at Hôpital Robert-Debré (AP-HP) in Paris, France, where she also serves as the coordinator for the RespiRare reference center for rare pediatric lung diseases. Her clinical and academic research focuses primarily on pediatric asthma, rare respiratory diseases, and optimizing cystic fibrosis management, with a particular emphasis on the long-term efficacy and trans-placental safety of next-generation CFTR modulators.
Joe Hsu, MD, MPH *Scientific Steering Committee Chair/Task Force Lead*	**Stanford University, USA**. Dr. Hsu is Assistant Professor of Medicine in Pulmonary and Critical Care at Stanford University. He is the director of the Stanford Lung Graft Versus Host Disease (GVHD) clinic. Dr. Hsu's focus is on transplant-related immunology, lung GVHD, Chronic Obstructive Pulmonary Disease (COPD), and infectious disease. His lab work is focused on translational research with an emphasis on pulmonary diseases in immunocompromised persons.

Name *Leadership Role in Conference*	**Bio**
Stephen Juvet, MD, PhD	**University of Toronto, Canada**. Dr. Juvet is an Associate Professor of Medicine at the University of Toronto and a clinician-scientist and pulmonologist with the Toronto Lung Transplant Program at University Health Network. His research is centered on transplantation immunology, with particular interests in chronic lung allograft dysfunction, transplant rejection, immune tolerance, and the development of regulatory T cell-based therapies to improve long-term transplant outcomes.
Carla Kim, PhD	**Harvard Medical School, USA**. Dr. Kim is the Boston Children's Hospital Professor of Pediatrics in the Field of Regenerative Medicine and Professor of Genetics at Harvard Medical School. Her research focuses on lung stem and progenitor cell biology, lung regeneration, and the mechanisms underlying lung cancer development and repair.
Yu Kuang Lai, MD	**Stanford University, USA**. Dr. Lai is a Clinical Assistant Professor within the Division of Pulmonary, Allergy, and Critical Care Medicine at Stanford. She has a dedicated focus on pulmonary hypertension, advanced obstructive lung diseases, and lung complications associated with allogeneic stem cell and bone marrow transplants, such as graft-versus-host disease (GVHD) and bronchiolitis obliterans syndrome. Her research focuses on the pathophysiology, diagnostic biomarkers, and therapeutic outcomes of pulmonary vascular diseases and post-transplant pulmonary complications to improve patient management in critical care settings.
Anita Lawitschka, MD, PhD	**St. Anna Children's Hospital, Medical University Vienna and St. Anna Children's Cancer Research Institute, Vienna, Austria**. Dr. Lawitschka is an Associate Professor at the Medical University of Vienna and serves as the Head of the Stem Cell Transplantation (SZT) Outpatient Clinic and Day Hospital at St. Anna Children's Hospital. She specializes in pediatric oncology and hematology, with a dedicated focus on managing long-term complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), specifically chronic graft-versus-host disease (cGVHD). Her research centers on transplant immunology, biomarker discovery, and optimizing targeted second-line therapies for cGVHD. She is a cofounding member of the German-Austrian-Swiss GVHD consortium.
Catherine Lee, MD, MS *Breakout Lead*	**Fred Hutchinson Cancer Center, USA**. Dr. Lee is an Associate Professor at the University of Washington School of Medicine, Division of Hematology and Oncology and an Associate Professor at FHCC in the Clinical Research Division. Her clinical and research activities are focused on chronic graft-versus-host disease (GVHD) and other late effects of transplantation, implementing interventions to improve access to high-quality transplant and post-transplant care and optimizing the long-term health and quality of life of patients who have received stem cell transplantation or other immune-cellular therapies.

Name *Leadership Role in Conference*	**Bio**
Stephanie Lee, MD, MPH *Special Advisor*	**Fred Hutchinson Cancer Center, USA**. Dr. Lee is a professor at the University of Washington School of Medicine, Division of Hematology and Oncology and a professor at FHCC in the Clinical Research Division. She is the Research Director of Long-Term Follow-Up at FHCC. Dr. Lee's research centers on improving BMT outcomes and quality of life for survivors, with a particular focus on chronic graft-versus-host disease (GVHD). She leads a nationwide research network that focuses on improving the understanding of chronic GVHD and the best ways to prevent, diagnose and treat it.
Guy Livneh	**Palo Alto, California, USA**. Guy Livneh is a California-based patient advocate, leukemia survivor, and bone marrow transplant recipient who is dedicated to advancing patient-centered innovation in healthcare. Drawing on his personal experience navigating transplantation and survivorship, he works to raise awareness of patient needs and improve outcomes through advocacy, education, and healthcare technology initiatives. His interests include long-term transplant survivorship, patient engagement, and leveraging innovative technologies to reduce the burden of care and improve quality of life for patients and families
Toby Maher, MD, PhD	**University of Southern California, Los Angeles, USA**. Dr. Maher is a Professor of Clinical Medicine and Director of Interstitial Lung Disease at the Keck School of Medicine of the University of Southern California. His clinical and research interests focus on idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases, biomarker discovery, and the development of novel therapies through translational research and clinical trials.
Andreas Mall	**Germany**. Andreas Mall is a retired global business executive who spent more than four decades with an international energy company, holding leadership roles across multiple countries and regions. He is a devoted husband and the proud father of six biological and adopted children. Following a diagnosis of myelodysplastic syndrome (MDS) in 2022, he underwent a bone marrow transplant. He subsequently developed bronchiolitis obliterans syndrome (BOS), which inspired a deep commitment to understanding his condition and advocating for greater awareness of transplant-related lung complications. Drawing on both his professional and personal experiences, he actively shares information and perspectives to support patients, caregivers, and the broader transplant community.
Patrick Mellors, MD	**Dartmouth-Hitchcock Medical Center, USA**. Dr. Mellors is an Assistant Professor of Medicine at the Geisel School of Medicine at Dartmouth and a stem cell transplant physician at Dartmouth Cancer Center. His research focuses on the multi-omic characterization of peripheral blood and tissue T cell immunology in graft-versus-host disease, using patient-derived samples to better understand disease biology and treatment response.

Name *Leadership Role in Conference*	**Bio**
Veronique Meignin, MD, PhD	**Hopital St. Louis University of Paris, France**. Dr. Meignin is a pathologist in the Department of Anatomical and Cytological Pathology at Hôpital Saint-Louis in Paris, France. Dr. Meignin's research focuses on hematopathology, pulmonary pathology, and transplant-related complications, including the histopathologic characterization of noninfectious lung complications following allogeneic hematopoietic stem cell transplantation. Her work also encompasses lymphoid malignancies, immune-mediated disorders, rare pulmonary diseases, and clinicopathologic studies that advance the understanding of pulmonary and hematologic complications in immunocompromised patients.
David Michonneau, MD, PhD	**University Paris Cité, France**. Dr. Michonneau is a Professor of Hematology at Université Paris Cité and a hematologist at Hôpital Saint-Louis. He leads the Translational Immunology in Immunotherapy and Hematology (TIGITH) research team at the Saint-Louis Research Institute. His clinical and research interests focus on allogeneic hematopoietic cell transplantation, graft-versus-host disease (GVHD), relapse prevention, immunotherapy, and the application of multi-omics and artificial intelligence approaches to improve transplant outcomes and immune-mediated hematologic diseases.
John Murray, RGN, MSc	**National Health Services, UK**. Professor Murray is the Honorary Clinical Chair and Advanced Practice Lead at The Christie NHS Foundation Trust in Manchester, UK. A highly accomplished oncology nurse clinician, his research interests focus on improving long-term patient outcomes following bone marrow transplantations, with a specific emphasis on the management of graft-versus-host disease (GvHD), the late effects of transplantation, and the optimized care of hematological malignancies.
Sophie Paczesny, MD, PhD *Scientific Steering Committee Chair/Task Force Lead*	**Medical University of South Carolina, USA**. Dr. Paczesny is a Professor in the Department of Pharmacology and Immunology as well as Co-Leader of the Cancer Biology and Immunology Program at the Hollings Cancer Center. Dr. Paczesny is currently an elected Director of Laboratory Science of the American Society for Transplantation and Cellular Therapy. She has pioneered the study of proteomics/biomarkers for complications post allogeneic HSCT and is now transitioning the laboratory work into clinical practice. She also has extensive expertise in the cancer immune tumor microenvironment, inflammation and alarmins, T lymphocyte biology and mechanisms of immunity and tolerance as well as translating novel drug-targetable biomarkers to treatment.
Steven Pavletic, MD, PhD *Scientific Steering Committee Chair/Task Force Lead*	**NIH/NCI Emeritus, USA and Croatia**. Dr. Pavletic is an NIH Scientist Emeritus. As a world-renowned expert in chronic graft-versus-host disease (cGVHD), he has led national and international efforts to develop consensus guidelines for cGVHD clinical trials. Dr. Pavletic was a Senior Clinician in the Immune Deficiency Cellular Therapy Program and was named a Top Ten Clinical Research Achievement awardee by the Clinical Research Forum in 2022. He directed the NIH cGVHD Study Group and the NIH Myeloid Malignancies Clinical Program.

Name *Leadership Role in Conference*	**Bio**
José A. Pérez-Simón, MD, PhD *Breakout Lead*	**Virgen del Rocío University Hospital, Spain**. Dr. Pérez-Simón is a Professor of Medicine and Head of the Hematology and Hemotherapy Service at Virgen del Rocío University Hospital in Seville, Spain. He is also a senior investigator at the Institute of Biomedicine of Seville (IBiS), where he leads translational research in hematopoietic cell transplantation, cellular therapies, graft-versus-host disease, and immunotherapy. His research focuses on improving outcomes for patients with hematologic malignancies through innovative immunotherapy and transplant strategies.
Iskra Pusic, MD, MSCI	**Washington University St. Louis, USA**. Dr. Pusic is a Professor of Medicine in the Division of Oncology at Washington University School of Medicine in St. Louis and a transplant physician specializing in hematologic malignancies, hematopoietic cell transplantation, and cellular therapies. Dr. Pusic's research focuses on the prevention and treatment of acute and chronic graft-versus-host disease (GVHD), long-term complications following allogeneic hematopoietic stem cell transplantation, transplant survivorship, and strategies to improve outcomes for patients with leukemia and myelodysplastic syndromes after transplantation. *Acknowledgement: Thank you, Dr. Pusic, for your contribution as an external reviewer.*
Jonathan H. Rayment, MDCM, MSc	**University of British Columbia, Canada**. Dr. Rayment is a Pediatric Respirologist at BC Children's Hospital and an Associate Professor in the Department of Pediatrics at the University of British Columbia. He is also Medical Lead for Canada's clinical trial network, CF CanACT. His research centers on the development, validation, and implementation of novel physiological and imaging biomarkers to detect and monitor early lung disease in children with the goal of improving lung-health outcomes for children living with cystic fibrosis, inborn errors of immunity, and rare pediatric lung diseases.
Paul Robinson, MD	**University of Queensland, Australia**. Dr. Robinson is a Senior Staff Specialist in the Department of Respiratory Medicine at The Children's Hospital at Westmead and a Clinical Professor within the Discipline of Pediatrics and Child Health at the University of Sydney. He is the Director of the Australian Central Over-Reading Centre (CORC), where he leads international standardization initiatives for lung function testing. His research centers on utilizing novel, complex lung function and imaging tools to detect early lung disease and improve long-term monitoring.

Name *Leadership Role in Conference*	**Bio**
Matthew Rutter, BSc, MSc	**Cambridge University Hospitals, UK**. Matthew Rutter is the Lead Respiratory Physiologist at Cambridge and Vice Chair of the Association of Respiratory Technology and Physiology professional body. As a teenager, he underwent a bone marrow transplant and subsequently developed graft-versus-host disease affecting his lungs, requiring regular pulmonary function testing. His firsthand experience as a patient inspired his career in respiratory physiology and continues to shape his commitment to delivering high-quality, patient-centered care. In addition to his clinical leadership role, he has contributed extensively to the development of national standards and quality improvement initiatives in respiratory physiology.
Alicja Sadowska-Klasa, MD	**Medical University of Gdánsk, Poland**. Dr. Sadowska-Klasa is an Associate Professor at the Medical University of Gdańsk, Poland, and an Affiliate Investigator at Fred Hutchinson Cancer Center in Seattle, USA. Her research focuses on infectious complications after hematopoietic cell transplantation, particularly CMV infection, and on understanding the associations between infectious complications and graft-versus-host disease.
Hélène Salvator, MD, PhD	**Hospital Foch, France**. Dr. Salvator is a Professor in the Department of Pulmonology at Hôpital Foch. Her clinical and translational research centers on respiratory complications of inherited immune deficiencies and hematological diseases (infectious diseases, lung GvHD). Her basic work in the Molecular Virology and Immunology Unit (U1369) addresses lung immunopathology in the setting of immunodeficiency (impact of anti GM-CSF autoantibodies on human lung macrophages, respiratory epithelial deficiency in case of STAT3 deficiency).
Clare Sander, MD	**Cambridge University Hospital, UK**. Dr. Sander is an Affiliated Assistant Professor in Clinical Medicine, Respiratory teaching lead and College lecturer in Medicine and the East of England Respiratory Training Program Director. She is a Consultant Respiratory Physician at Addenbrookes Hospital, specializing in acute and chronic respiratory infections including TB, NTM and respiratory complications of both primary and secondary immunodeficiency. She runs a respiratory haematology clinic and established a group of Chest physicians in the UK who work with complications of haemato-oncological malignancy, including allogeneic transplant and undertaken research into diagnosis of fungal infections in this patient cohort.

Name *Leadership Role in Conference*	**Bio**
Stefanie Sarantopoulos, MD, PhD	**Duke University School of Medicine, USA**. Dr. Sarantopoulos is Chief of Hematologic Malignancies and Cellular Therapy at Duke University School of Medicine, where she also serves as the James Wyngaarden Distinguished Professor of Medicine, Professor of Medicine, and Professor of Integrative Immunobiology. Her research focuses on the immunologic mechanisms underlying chronic graft-versus-host disease (cGVHD), particularly the role of B cells in disease development and progression. Her translational research aims to identify and target pathologic immune pathways in cGVHD, improve outcomes following hematopoietic cell transplantation, and develop novel therapeutic strategies for GVHD and other immune-mediated complications of transplantation. Her work also explores transplant survivorship, immune reconstitution, and cellular therapies. *Acknowledgement: Thank you, Dr. Sarantopoulos, for your contribution as an external reviewer.*
Hélène Schoemans, MD, PhD *Breakout Lead*	**University Hospitals of Leuven, Belgium**. Dr. Schoemans is an Assistant Professor of Medicine at KU Leuven and a hematologist, head of the Bone Marrow Transplant and CAR-T program at the University Hospitals of Leuven, Belgium. Her research interests center on GVHD, survivorship, eHealth and patient engagement in research and care. She is actively involved in international collaborations through the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR).
Kirk Schultz, MD, PhD	**University of British Columbia, Canada**. Dr. Schultz is a Professor of Pediatrics at the University of British Columbia and a Pediatric Hematologist/Oncologist at BC Children's Hospital in Vancouver, Canada. Dr. Schultz is the leader of the pediatric-focused Applied Biomarkers in Late effects (ABLE) Network focused on developing chronic GvHD (cGvHD) Biomarkers to guide treatment and better under cGvHD biology.
Shiv Shanthikumar, MBBS, PhD	**University of Melbourne, Australia**. Dr. Shanthikumar is an Associate Professor affiliated with the University of Melbourne, the Murdoch Children's Research Institute, and The Royal Children's Hospital in Melbourne, Australia. A pediatric respiratory specialist, his clinical and research interests in pulmonary GVHD include assessing novel tests for lung function, infection and inflammation, assessing clinical practice internationally, and development of clinical practice guidelines.
Husham Sharifi, MD *Chair/Task Force Lead*	**Stanford University, USA**. Dr. Sharifi is a Clinical Assistant Professor of Pulmonary, Allergy, and Critical Care Medicine at Stanford University School of Medicine. A physician-engineer, he cares for and studies patients with pulmonary complications after hematopoietic cell and lung transplantation. His research applies artificial intelligence to advanced chest imaging, including quantitative CT, to detect transplant-related pulmonary fibrosis and pulmonary graft-versus-host disease at their earliest stages.

Name *Leadership Role in Conference*	**Bio**
Ajay Sheshadri, MD, MSCI *Chair/Task Force Lead*	**MD Anderson Cancer Center, USA**. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. A pulmonologist and physician-scientist, his clinical and research work focuses on pulmonary complications of cancer and hematopoietic cell transplantation, including lung graft-versus-host disease (GVHD), immunotherapy-related lung toxicities, and advanced thoracic imaging.
Danielle Stahlbaum, MD, MS *Breakout Lead*	**University of Michigan, USA**. Dr. Stahlbaum is a Clinical Assistant Professor of Pulmonary and Critical Care Medicine at the University of Michigan. She serves as co-director of the multidisciplinary Lung Graft-versus-Host Disease Clinic and director of the University of Michigan Rare Lung Disease Program. Her clinical and research interests focus on pulmonary diseases, with particular expertise in pulmonary complications of cancer therapies and drug toxicities, including graft-versus-host disease and immune checkpoint inhibitor pneumonitis.
Jeffrey Sturek, MD, PhD *Chair/Task Force Lead*	**University of Virginia School of Medicine, USA**. Dr. Sturek is an Associate Professor of Pulmonary and Critical Care Medicine at the University of Virginia. His clinical expertise is in oncopulmonology, with a focus on pulmonary toxicities and complications arising from cancer therapies and stem cell transplantation. His research investigates lung inflammation and fibrosis, particularly the role of B-cell immune responses in interstitial lung disease and pulmonary injury. *Acknowledgement: Thank you, Dr. Sturek, for your contribution as an external reviewer.*
Jamie Todd, MD, MHS *Breakout Lead*	**Duke University, USA**. Dr. Todd is an Associate Professor of Medicine in the Division of Pulmonary, Allergy and Critical Care Medicine at Duke University and a transplant pulmonologist at Duke Health. Her clinical expertise includes lung transplantation, idiopathic pulmonary fibrosis (IPF), and advanced lung disease. Her research focuses on the biologic and genetic mechanisms underlying pulmonary fibrosis and chronic lung allograft dysfunction (CLAD), with the goal of improving the diagnosis, prevention, and treatment of chronic lung transplant rejection.
Jane Turner, MD	**McMaster University, Canada**. Dr. Turner is an Assistant Professor of Medicine in the Division of Respirology at McMaster University. Her clinical and research interests include pulmonary complications of hematopoietic stem cell transplantation, chronic graft-versus-host disease, bronchiolitis obliterans syndrome, and immune therapy-related lung disease. Her work focuses on improving early detection and monitoring of transplant-related pulmonary complications through innovative approaches such as home spirometry and telemonitoring.

Name *Leadership Role in Conference*	**Bio**
Stijn Verleden, PhD	**University of Antwerp, Wilrijk, Belgium**. Dr. Verleden is an Associate Research Professor at the University of Antwerp, where he is affiliated with the Antwerp Surgical Training, Anatomy and Research Centre (ASTARC). He also serves as a scientific staff member at the Antwerp University Hospital (UZA). His research focuses on advanced lung imaging, small airway disease, lung transplantation, chronic lung allograft dysfunction, and the structural changes that occur in the lung during disease, aging, and transplant rejection.
Gerald Weinhouse, MD	**Dana-Farber Cancer Institute/Harvard University, USA**. Dr. Weinhouse is a pulmonologist at Dana-Farber Cancer Institute and Brigham and Women's Hospital and serves as an Assistant Professor of Medicine at Harvard Medical School. His clinical interests focus on lung disease in patients with cancer, including pulmonary complications related to cancer treatment and stem cell transplantation. His academic work spans pulmonary and critical care medicine, with research contributions in critical illness, sleep and delirium in the ICU, and oncologic pulmonary disorders.
Kirsten M. Williams, MD *Chair/Task Force Lead*	**Emory University School of Medicine, USA**. Dr. Williams is a Professor of Pediatrics at Emory University School of Medicine and a pediatric hematologist/oncologist at Children's Healthcare of Atlanta where she specializes in pediatric blood and marrow transplantation and cellular therapy. Her translational research focuses on improving outcomes for children undergoing hematopoietic cell transplantation, with particular expertise in graft-versus-host disease, graft failure, leukemia relapse, and transplant-related lung complications.
Daniel Wolff, MD *Scientific Steering Committee Chair/Task Force Lead*	**University Hospital Regensburg, Germany**. Dr. Wolff is chair of the multidisciplinary GVHD Center of the University Hospital Regensburg, Germany. His work focuses on pathophysiology and treatment of chronic GVHD. He is a member of the steering committee of the NIH Consensus on cGVHD 2020. He is chair of the German-Austrian-Swiss GVHD consortium. Dr. Wolff is also part of the Costem Faculty.
Hemang Yadav, MBBS	**Mayo Clinic Minnesota, USA**. Dr. Yadav is an Associate Professor of Medicine and Vice Chair for Research in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at Mayo Clinic in Rochester, Minnesota. His clinical and research interests center on transplant and oncology critical care, pulmonary complications of hematopoietic cell transplantation, and pulmonary function test methodology. His NIH-funded research program focuses on pulmonary complications and PFT-based risk stratification after HCT, and sedation-related adverse events in the ICU.

Name *Leadership Role in Conference*	**Bio**
Greg Yanik, MD *Breakout Lead*	**University of Michigan, USA**. Dr. Yanik is a Professor of Pediatric Hematology/Oncology, Clinical Professor of Pediatrics and Internal Medicine, and Medical Director of the Pediatric Blood and Marrow Transplant Program at the University of Michigan. His clinical expertise includes pediatric hematologic malignancies, blood and marrow transplantation, cellular therapies, and transplant-related lung injury. His research focuses on improving outcomes after hematopoietic cell transplantation, with a particular interest in pulmonary complications, graft-versus-host disease, and novel cellular therapies for pediatric cancers.
Matthew Zinter, MD	**University of California San Francisco, USA**. Dr. Zinter is an Associate Professor of Pediatrics at the University of California, San Francisco (UCSF), Director of the Pediatric Immunocompromised Critical Care Program, and an attending physician in the Pediatric Intensive Care Unit at UCSF Benioff Children's Hospitals. His clinical and research interests focus on critical illness, lung injury, infection, and organ dysfunction in children with cancer, immunodeficiencies, and those undergoing hematopoietic cell transplantation. His translational research seeks to better understand the biological mechanisms of pulmonary complications and critical illness in immunocompromised children to develop improved diagnostic and therapeutic strategies.